Recursion Pharmaceuticals ( RXRX +1.91%) was in the headlines on Monday, and for the right reason. One of the biotech company ...

Recursion Pharmaceuticals, a drug discovery company that applies artificial intelligence to biology, is shoring up its technology platform by buying two startups that bolster its chemistry ...

Recursion Pharmaceuticals (NASDAQ:RXRX) gained 7% on Monday after releasing encouraging Phase 2 results for REC-4881, its ...

This Q&A is part of a weekly series of posts highlighting common questions encountered by technophiles and answered by users at Stack Exchange, a free, community-powered network of 100+ Q&A sites.

Few would place Recursion Pharmaceuticals ( RXRX +8.44%), a little-known biotech company, in the same league as these tech giants when it comes to AI stocks. But could the small drugmaker actually ...

Shares of Recursion Pharmaceuticals are trading higher Monday after the company reported positive data from an ongoing trial.

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

Ongoing Phase 1b/2 Trial of the Allosteric MEK1/2 Inhibitor REC-4881 as Monotherapy (FAP): Updated Safety and Efficacy Najat Khan, Ph.D ., Chief R&D and Chief Commercial Officer and incoming CEO and ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...